Week In Review: China's Luxin Invests In $215 Million Funding For Intarcia's Long-Term Diabetes Device
September 17, 2016 at 15:30 PM EDT
Luxin Venture Capital of Shandong Province participated in the first closing of the latest funding round for Boston's Intarcia Therapeutics.
